PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study

Autor: Shing-Hwa Liu, Chen-Hsun Hsu, Yen-Ling Chiu, Jun-Ren Dong, Fu-Shun Hsu, Wei-Chou Lin, Shao-Ping Yang, Kuo-How Huang, Shih-Chen Chang, Ruei-Je Chang, Yueh-Tang Chen, Kuan-Lin Kuo, Shih-Ming Liao

Publikováno v: International Journal of Molecular Sciences
Volume 22
Issue 21
International Journal of Molecular Sciences, Vol 22, Iss 11706, p 11706 (2021)

Cisplatin-based chemotherapy is the standard treatment for bladder urothelial carcinoma (UC). Most patients experience chemoresistance, the primary cause of treatment failure, which leads to disease relapse. The underlying mechanism of chemoresistanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1342a9d7a19b70616e2a674e409757e9